1968-51-0

Basic information

• Product Name: 2-(Hydroxymethyl)-3-hydroxy-4H-pyran-4-one
• Synonyms: 2-(Hydroxymethyl)-3-hydroxy-4H-pyran-4-one;2-Hydroxymethyl-3-hydroxy-4H-pyran-4-one;3-Hydroxy-2-(hydroxymethyl)-4H-pyran-4-one;3-hydroxy-2-(hydroxymethyl)pyran-4-one
• CAS NO: 1968-51-0
• Molecular Formula: C₆H₆O₄
• Molecular Weight: 142.11
• Mol File: 1968-51-0.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(Hydroxymethyl)-3-hydroxy-4H-pyran-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(Hydroxymethyl)-3-hydroxy-4H-pyran-4-one(1968-51-0)
• EPA Substance Registry System: 2-(Hydroxymethyl)-3-hydroxy-4H-pyran-4-one(1968-51-0)

Safety Data

• Hazardous Substances Data: 1968-51-0(Hazardous Substances Data)

Usage

Molecular weight

128.12 g/mol

Appearance

White crystalline solid

Solubility

Soluble in water, slightly soluble in ethanol, and insoluble in ether

Occurrence

Commonly found in foods such as honey, fruit juices, and alcoholic beverages.

Antioxidant properties

Has the potential to prevent or slow down the oxidation of other molecules, which can lead to cellular damage.

Medical potential

Has shown potential as a treatment for certain medical conditions.

Negative health effects

High consumption of HMF has been linked to an increased risk of cancer.

Upstream product

• 63167-69-1 methyl 2,3-O-isopropylidene-α-D-mannopyranoside 
• 617-04-9 (2R,3S,4S,5S,6S)-2-(hydroxymethyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 60249-17-4 6-methoxy-2H-pyran-3(6H)-one 
• 98-00-0 (2-furyl)methyl alcohol 
• 496-63-9 3-hydroxy-pyran-4-one 
• 50-00-0 formaldehyd 
• 32361-32-3 methyl β-D-xylo-hexopyranoside-4-ulose 
• 623-11-0 1-methyl-4-nitrosobenzene 
• 547-92-2 (1R)-N,N'-dicarbamimidoyl-O⁴-[3-formyl-O²-(2-methylamino-2-deoxy-α-L-glucopyranosyl)-α-L-lyxofuranosyl]-streptamine; hydrochloride 
• 19969-71-2 2,5-dimethoxy-2-hydroxymethyl-2,5-dihydrofuran 
• 74425-84-6 4-Bromo-6-methoxy-2H-pyran-3(6H)-one 

Downstream Products

• 216579-21-4 8-oxo-4,8-dihydro-2-phenyl-4H-pyrano[3,2-d]-m-dioxin 
• 119736-15-1 2-(hydroxymethyl)-3-(phenylmethoxy)-4H-pyran-4-one 
• 119736-16-2 3-(benzyloxy)-1-((tert-butoxycarbonyl)amino)-4-oxo-1,4-dihydropyridine-2-carboxylic acid ethyl ester 
• 106203-49-0 3-(p-nitrobenzyloxy)-4H-pyran-4-one-2-carboxaldehyde 
• 106203-48-9 2-hydroxymethyl-3-(p-nitrobenzyloxy)-4H-pyran-4-one 

Relevant articles and documents

-

-

Preparation method of hydroxyl pyrone compound

The invention provides a preparation method of 3-hydroxyl-2-(hydroxymethyl)-4H-pyran-4-one, and belongs to the field of pharmaceutical and chemical industry. The method comprises the following steps:reacting ethoxy pyran and ketone compounds with p-toluen

Synthesis method of 3-(benzyloxy)-4-oxo-4H-pyran-2-carboxylic acid

The invention discloses a synthesis method of 3-(benzyloxy)-4-oxo-4H-pyran-2-carboxylic acid. The synthesis method takes furfuryl alcohol as a starting raw material and four-step reaction including rearrangement, addition, hydroxyl protection and oxidization is carried out; the total mol yield of a synthesis route is greater than 32 percent; the synthesis method has the characteristics of relatively moderate reaction conditions and the like, and the yield and purity of the 3-(benzyloxy)-4-oxo-4H-pyran-2-carboxylic acid are remarkably improved; meanwhile, the synthesis method has the advantagesof detailed technological operation steps, specific parameters, controllable conditions and stable technology, and can realize industrial large-batch production.

Orally active iron (III) chelators

A novel 3-hydroxypyridin-4-one compound of formula I is provided wherein R is hydrogen or a group that is removed by metabolism in vivo to provide the free hydroxy compound, R1 is an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted by a hydroxy group or a carboxylic acid ester, sulpho acid ester or a C1-6 alkoxy, C6-aryloxy or C7-10aralkoxy ether thereof, R3 is selected from hydrogen and C1-6alkyl; and R4 is selected from hydrogen, C1-6alkyl and a group as described for R2; characterised in that R2 is selected from groups —CONH—R5??(i) —CH2NHCO—R5??(ii) —SO2NH—R5??(iii) —CH2NHSO2—R5??(iv) —CR6R6OR7??(v) —CONHCOR5??(viii) ?wherein R5 is selected from hydrogen and optionally hydroxy, alkoxy, or aralkoxy substituted C1-13 alkyl, aryl and C71-13 aralkyl, R6 is independently selected from hydrogen, C1-13 alkyl, aryl and C7-13 aralkyl, and R7 is selected from hydrogen, C1-13 alkyl, aryl and C7-13 aralkyl or a pharmaceutically acceptable salt of any such compound with the proviso that when R7 is hydrogen, R6 is not selected from aryl and with the proviso that the compound is not 1-ethyl-2-(1′-hydroxyethyl)-3-hydroxypyridin-4-one.